|
1
|
Litvinov SV, Bakker HA, Gourevitch MM,
Velders MP and Warnaar SO: Evidence for a role of the epithelial
glycoprotein 40 (Ep-CAM) in epithelial cell-cell adhesion. Cell
Adhes Commun. 2:417–428. 1994. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Gastl G, Spizzo G, Obrist P, Dünser M and
Mikuz G: Ep-CAM overexpression in breast cancer as a predictor of
survival. Lancet. 356:1981–1982. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Heinzelmann-Schwarz VA, Gardiner-Garden M,
Henshall SM, et al: Overexpression of the cell adhesion molecules
DDR1, Claudin 3, and Ep-CAM in metaplastic ovarian epithelium and
ovarian cancer. Clin Cancer Res. 10:4427–4436. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Songun I, Litvinov SV, van de Velde CJ,
Pals ST, Hermans J and van Krieken JH: Loss of Ep-CAM (CO17-1A)
expression predicts survival in patients with gastric cancer. Br J
Cancer. 92:1767–1772. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Spizzo G, Went P, Dirnhofer S, et al:
Overexpression of epithelial cell adhesion molecule (Ep-CAM) is an
independent prognostic marker for reduced survival of patients with
epithelial ovarian cancer. Gynecol Oncol. 103:483–488. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Kimura H, Kato H, Faried A, et al:
Prognostic significance of EpCAM expression in human esophageal
cancer. Int J Oncol. 30:171–179. 2007.PubMed/NCBI
|
|
7
|
Shim HS, Yoon BS and Cho NH: Prognostic
significance of paired epithelial cell adhesion molecule and
E-cadherin in ovarian serous carcinoma. Hum Pathol. 40:693–698.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Schmidt M, Hasenclever D, Schaeffer M, et
al: Prognostic effect of epithelial cell adhesion molecule
overexpression in untreated node-negative breast cancer. Clin
Cancer Res. 14:5849–5855. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Schmidt M, Petry IB, Böhm D, et al: Ep-CAM
RNA expression predicts metastasis-free survival in three cohorts
of untreated node-negative breast cancer. Breast Cancer Res Treat.
125:637–646. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Akita H, Nagano H, Takeda Y, et al: Ep-CAM
is a significant prognostic factor in pancreatic cancer patients by
suppressing cell activity. Oncogene. 30:3468–3476. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pietzner K, Woopen H, Richter R, et al:
Expression of epithelial cell adhesion molecule in paired tumor
samples of patients with primary and recurrent serous ovarian
cancer. Int J Gynecol Cancer. 23:797–802. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Battista MJ, Cotarelo C, Jakobi S, et al:
Overexpression of epithelial cell adhesion molecule protein is
associated with favorable prognosis in an unselected cohort of
ovarian cancer patients. J Cancer Res Clin Oncol. 140:1097–1102.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Seligson DB, Pantuck AJ, Liu X, et al:
Epithelial cell adhesion molecule (KSA) expression: pathobiology
and its role as an independent predictor of survival in renal cell
carcinoma. Clin Cancer Res. 10:2659–2669. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Varga M, Obrist P, Schneeberger S, et al:
Overexpression of epithelial cell adhesion molecule antigen in
gallbladder carcinoma is an independent marker for poor survival.
Clin Cancer Res. 10:3131–3136. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Stoecklein NH, Siegmund A, Scheunemann P,
et al: Ep-CAM expression in squamous cell carcinoma of the
esophagus: a potential therapeutic target and prognostic marker.
BMC Cancer. 6(165)2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Choijamts B, Jimi S, Kondo T, et al:
CD133+ cancer stem cell-like cells derived from uterine
carcinosarcoma (malignant mixed Müllerian tumor). Stem Cells.
29:1485–1495. 2011.
|
|
17
|
Paniz Mondolfi AE, Jour G, Johnson M, et
al: Primary cutaneous carcinosarcoma: insights into its clonal
origin and mutational pattern expression analysis through
next-generation sequencing. Hum Pathol. 44:2853–2860. 2013.
|
|
18
|
Went PT, Lugli A, Meier S, et al: Frequent
EpCam protein expression in human carcinomas. Hum Pathol.
35:122–128. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Vincenzi B, Rossie E, Zoccoli A, et al:
Circulating tumor cells in soft tissue sarcomas. In: Poster
presented at 37th EMSO Congress; 2012; http://www.oxfordjournals.org/our_journals/annonc/downloads/annonc23s9-v2.pdfAccessed.
June. 2014
|
|
20
|
Sanchez-Carbayo M, Belbin TJ, Scotlandi K,
et al: Expression profiling of osteosarcoma cells transfected with
MDR1 and NEO genes: regulation of cell adhesion, apoptosis, and
tumor suppression-related genes. Lab Invest. 83:507–517. 2003.
View Article : Google Scholar
|
|
21
|
Barretina J, Caponigro G, Stransky N, et
al: The Cancer Cell Line Encyclopedia enables predictive modelling
of anticancer drug sensitivity. Nature. 483:603–607. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Schmelzer E and Reid LM: EpCAM expression
in normal, non-pathological tissues. Front Biosci. 13:3096–3100.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Herlyn M, Steplewski Z, Herlyn D and
Koprowski H: Colorectal carcinoma-specific antigen: detection by
means of monoclonal antibodies. Proc Natl Acad Sci USA.
76:1438–1442. 1979. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Patriarca C, Macchi RM, Marschner AK and
Mellstedt H: Epithelial cell adhesion molecule expression (CD326)
in cancer: a short review. Cancer Treat Rev. 38:68–75. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Gutzmer R, Li W, Sutterwala S, et al: A
tumor-associated glycoprotein that blocks MHC class II-dependent
antigen presentation by dendritic cells. J Immunol. 173:1023–1032.
2004. View Article : Google Scholar
|
|
26
|
Münz M, Kieu C, Mack B, Schmitt B, Zeidler
R and Gires O: The carcinoma-associated antigen EpCAM upregulates
c-Myc and induces cell proliferation. Oncogene. 23:5748–5758.
2004.PubMed/NCBI
|
|
27
|
Fagerberg J, Hjelm AL, Ragnhammar P,
Frödin JE, Wigzell H and Mellstedt H: Tumor regression in
monoclonal antibody-treated patients correlates with the presence
of anti-idiotype-reactive T lymphocytes. Cancer Res. 55:1824–1827.
1995.
|
|
28
|
Chelius D, Ruf P, Gruber P, et al:
Structural and functional characterization of the trifunctional
antibody catumaxomab. MAbs. 2:309–319. 2010. View Article : Google Scholar
|
|
29
|
Seimetz D, Lindhofer H and Bokemeyer C:
Development and approval of the trifunctional antibody catumaxomab
(anti-EpCAM × anti-CD3) as a targeted cancer immunotherapy. Cancer
Treat Rev. 36:458–467. 2010.
|
|
30
|
Ströhlein MA and Heiss MM: The
trifunctional antibody catumaxomab in treatment of malignant
ascites and peritoneal carcinomatosis. Future Oncol. 6:1387–1394.
2010.PubMed/NCBI
|
|
31
|
Bell SW, Kempson RL and Hendrickson MR:
Problematic uterine smooth muscle neoplasms. A clinicopathologic
study of 213 cases. Am J Surg Pathol. 18:535–558. 1994. View Article : Google Scholar : PubMed/NCBI
|
